1

Date:	3-31-202	21					
Your Name	:	_Xiaobin Shang					
Manuscrip	t Title:	TGFBI is involved in	the formation of po	lyploid cance	r cells and the	response to pa	clitaxel
Manuscrip	t number	(if known):	ATM-21-1698				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	X_NoneX_None	36 months
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or					
	educational events					
6	Payment for expert	_X_None				
	testimony					
_						
7	Support for attending meetings and/or travel	_X_None				
8	Patents planned, issued or	X_None				
	pending					
9	Participation on a Data	_X_None				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role	XNone				
	in other board, society,					
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	X_None				
12	Receipt of equipment,	<u>X</u> _None				
	materials, drugs, medical					
	writing, gifts or other					
	services					
13	Other financial or non-	X_None				
	financial interests					
DI -	Please summarize the above conflict of interest in the following box:					
716	ase summanize the above co	ommer of interest in the fo	nowing box.			

The authors have no conflicts of interest to declare.			

2

Date:	3-31-2021	
Your Name:	Bibo Yuan	
Manuscript Title:	TGFBI is invo	ved in the formation of polyploid cancer cells and the response to paclitaxel
Manuscript number	(if known):	ATM-21-1698

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X_None	
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	X None  X None	36 months
4	Consulting fees	_X_None	

_						
5	Payment or honoraria for	_X_None				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or educational events					
_		V. Nava				
6	Payment for expert	XNone				
	testimony					
-	Command for adding the	V Nava				
7	Support for attending meetings and/or travel	X_None				
8	Patents planned, issued or	X_None				
	pending					
9	Participation on a Data	_X_None				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role	_X_None				
	in other board, society,					
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	XNone				
12	Receipt of equipment,	_XNone				
	materials, drugs, medical					
	writing, gifts or other services					
13	Other financial or non-	X_None				
	financial interests					
DI-	aca cummariza tha abava a	auflict of interest in the fol	lauring have			

## Please summarize the above conflict of interest in the following box:

The authors have no conflicts of interest to declare.			

Please place an "X" next to the following statement to indicate your agreement:

3

Date:	3-31-2021	
Your Name:	Jingjing Li	
Manuscript Title:	TGFBI is involve	ed in the formation of polyploid cancer cells and the response to paclitaxe
Manuscript number	(if known):	ATM-21-1698

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial X_None	planning of the work
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	Time frame: past _X_None _X_None	36 months
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or					
	educational events					
6	Payment for expert	XNone				
	testimony					
7	Support for attending meetings and/or travel	_X_None				
8	Patents planned, issued or	X_None				
	pending					
9	Participation on a Data	_X_None				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role	XNone				
	in other board, society,					
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	X_None				
12	Receipt of equipment,	<u>X</u> _None				
	materials, drugs, medical					
	writing, gifts or other					
	services					
13	Other financial or non-	XNone				
	financial interests					
DI-	Please summarize the above conflict of interest in the following box:					
716	ase summanize the above co	ommer of interest in the fo	nowing box.			

The authors have no conflicts of interest to declare.				

4

Date:	3-31-2021		
Your Name:	Fangfang	Xi	
Manuscript Title:_	TGFBI is invo	lved in the formation of polyploid cancer cells and the response to paclit	axe
Manuscript numb	er (if known):	ATM-21-1698	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	All		planning of the work
1	All support for the present	X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time innition this item.		
		Time from a real	26
2		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
_	in item #1 above).		
3	Royalties or licenses	_X_None	
	-		
4	Consulting fees	_XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_X_None		
	testimony			
7	Support for attending meetings and/or travel	_XNone		
8	Patents planned, issued or	_X_None		
	pending			
9	Participation on a Data	X_None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	X_None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X_None		
12	Receipt of equipment,	X_None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	X_None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
			<del>-</del>	

The authors have no conflicts of interest to declare.	

Date:	3-31-2021	
Your Name:	Jingxin Mao_	
Manuscript Title:	_ TGFBI is involved in the fo	ormation of polyploid cancer cells and the response to paclitaxel
Manuscript num	ber (if known):	ATM-21-1698

5

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

5	Payment or honoraria for	X_None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
_	educational events				
6	Payment for expert	_X_None			
	testimony				
_					
7	Support for attending meetings and/or travel	_X_None			
8	Patents planned, issued or	X_None			
	pending				
9	Participation on a Data	_X_None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_X_None			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	_X_None			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	_X_None			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				

The authors have no conflicts of interest to declare.	

6

Date:	<u>3-31-2021</u>		_
Your Name:	Chen Zhang		_
Manuscript Title:	TGFBI is involved	I in the formation of polyploid cancer cells and the response to paclita	xel
Manuscript number (if	known):	ATM-21-1698	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	XNone	
5	Payment or honoraria for	_XNone	

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
	G ,		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	•		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		

# Please summarize the above conflict of interest in the following box:

The authors have no conflicts of interest to declare.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	3-31-2021	
Your Name:	Hongjing Jiang	
Manuscript Title:	TGFBI is involved in the formation of	of polyploid cancer cells and the response to paclitaxel
Manuscript number	(if known): ATM-21-1698	

7

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All according to the consequent		planning of the work
1	All support for the present	X_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_X_None	
4	Consulting fees	_XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_X_None		
	testimony			
7	Support for attending meetings and/or travel	_XNone		
8	Patents planned, issued or	_X_None		
	pending			
9	Participation on a Data	_X_None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	X None		
12	Receipt of equipment,	_XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	X_None		
	financial interests			
Pla	Please summarize the above conflict of interest in the following box:			
	ase sammanize the above to	on the form	ioning wow	

The authors have no conflicts of interest to declare.		

Date:	<u>3-31-2021</u>	
Your Name:	Guoyan Liu	
Manuscript Title:	TGFBI is involved in the forma	tion of polyploid cancer cells and the response to paclitaxel_
Manuscript numbe	r (if known): ATM-2	1-1698

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,	the Natural Science Fund of China	No. 81101673 and 81472761
	medical writing, article processing charges, etc.)	the Tianjin Science and Technology Committee	No. 14JCYBJC25300
	No time limit for this item.	Foundation Foundation	
	Time frame: past 36 months		
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
2	in item #1 above).	V AI	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or	_ <u>X</u> None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_X_None	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>X_</u> None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the f	ollowing hox:

The authors have no conflicts of interest to declare.		